Shares of Autolus Therapeutics Ltd – (NASDAQ:AUTL) have received a consensus rating of “Buy” from the six analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $44.00.

A number of research analysts have weighed in on the company. Wells Fargo & Co reissued a “buy” rating and set a $50.00 price target (up previously from $38.00) on shares of Autolus Therapeutics in a research note on Thursday, November 29th. HC Wainwright assumed coverage on Autolus Therapeutics in a report on Wednesday, October 24th. They set a “buy” rating for the company. Finally, Zacks Investment Research downgraded Autolus Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, November 30th.

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Autolus Therapeutics during the 2nd quarter worth $132,000. TD Asset Management Inc. acquired a new stake in Autolus Therapeutics in the 2nd quarter valued at $258,000. ING Groep NV acquired a new stake in Autolus Therapeutics in the 2nd quarter valued at $402,000. Bank of Montreal Can acquired a new stake in Autolus Therapeutics in the 2nd quarter valued at $429,000. Finally, Janus Henderson Group PLC acquired a new stake in Autolus Therapeutics in the 2nd quarter valued at $498,000. Institutional investors and hedge funds own 44.20% of the company’s stock.

Shares of Autolus Therapeutics stock traded up $1.51 during trading hours on Friday, reaching $42.69. 88,463 shares of the company’s stock were exchanged, compared to its average volume of 66,577. Autolus Therapeutics has a 52-week low of $19.17 and a 52-week high of $53.24.

Autolus Therapeutics Company Profile

Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom.

Read More: Are all No-Load Funds Equal?

Analyst Recommendations for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.